rs10938397 — GNPDA2

GNPDA2 — The Hexosamine Pathway's Weight Regulator

rs10938397 sits in a regulatory region near GNPDA2 (glucosamine-6-phosphate deaminase 2) on chromosome 4p12 and was identified in the landmark GIANT consortium GWAS¹¹ GIANT consortium GWAS
Willer et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature Genetics, 2009 as one of six new obesity-associated loci, with a per-allele BMI increase of 0.19 kg/m² and a combined p-value of 3.4×10⁻¹⁶ across >90,000 individuals. The G allele is the risk allele. Unlike FTO — which acts through adipocyte thermogenesis — and MC4R and TMEM18 — which act through appetite suppression — GNPDA2 operates through a distinct metabolic channel: the hexosamine signaling pathway²² hexosamine signaling pathway
One of the main nutrient-sensing pathways, directing glucose and amino acid metabolism toward cellular signaling rather than energy storage.

The Mechanism

GNPDA2 encodes an allosteric enzyme that catalyzes the reversible conversion of D-glucosamine-6-phosphate to D-fructose-6-phosphate and ammonium. This reaction sits at a critical junction: it opposes the action of GFAT (glutamine-fructose-6-phosphate amidotransferase³³ glutamine-fructose-6-phosphate amidotransferase
The rate-limiting enzyme feeding into the hexosamine biosynthesis pathway, which produces UDP-GlcNAc for protein O-GlcNAcylation and cellular signaling), functioning as a brake on hexosamine flux. The hexosamine pathway is a nutrient sensor — its output, UDP-GlcNAc, modifies proteins and influences insulin signaling, gene expression, and cellular metabolism in proportion to glucose availability.

GNPDA2 is highly expressed in the hypothalamus⁴⁴ highly expressed in the hypothalamus
Specifically in the arcuate nucleus (ARC), dorsomedial hypothalamus (DMH), lateral hypothalamic area (LHA), and paraventricular nucleus (PVN) and in adipose tissue, with lower expression in muscle and liver. A 2021 functional study⁵⁵ 2021 functional study
Central administration of a GNPDA2 antagonist into the third ventricle of rats; Frontiers in Nutrition, 2021 showed that central GNPDA2 inhibition does not alter food intake or body weight — ruling out appetite as the primary mechanism — but causes glucose intolerance during an intraperitoneal glucose challenge without changing insulin levels. This positions GNPDA2 as a central regulator of glucose handling, with effects mediated through insulin sensitivity rather than insulin secretion or appetite drive.

In adipose tissue, the picture is complementary: a 2019 study⁶⁶ 2019 study
Wu et al. GNPDA2 Gene Affects Adipogenesis and Alters the Transcriptome Profile of Human Adipose-Derived Mesenchymal Stem Cells. International Journal of Endocrinology, 2019 demonstrated that overexpression of GNPDA2 in human adipose-derived mesenchymal stem cells enhances lipid droplet accumulation and adipocyte differentiation, while knockdown suppresses adipogenesis. The transcriptome changes affected genes involved in fatty acid metabolism, lipid modification, and glucose homeostasis.

The Evidence

The association is among the most robustly replicated in obesity genetics. The original GIANT discovery in 32,000 European subjects with replication in 59,000 more⁷⁷ 32,000 European subjects with replication in 59,000 more
Willer et al. Nature Genetics, 2009 was confirmed in a 249,796-individual meta-analysis (Speliotes et al. Nature Genetics, 2010⁸⁸ Speliotes et al. Nature Genetics, 2010) and the largest BMI GWAS to date, 339,224 individuals⁹⁹ 339,224 individuals
Locke et al. Nature, 2015.

In a Danish cohort of 18,014 adults, the G allele was associated with OR 1.15 for obesity (p = 1.1×10⁻⁴)¹⁰¹⁰ OR 1.15 for obesity (p = 1.1×10⁻⁴)
Sandholt et al. Studies of Metabolic Phenotypic Correlates of 15 Obesity Associated Gene Variants. PLOS ONE, 2011, BMI increase of 0.28 kg/m² per allele, and a 0.61 cm increase in waist circumference. Nominal associations with fasting insulin and HOMA-IR¹¹¹¹ HOMA-IR
Homeostatic Model Assessment of Insulin Resistance — a measure of insulin sensitivity derived from fasting glucose and insulin were also observed but did not survive correction for multiple testing.

In Mexican children, the association was stronger: OR 1.30 for obesity (p = 1.34×10⁻³)¹²¹² OR 1.30 for obesity (p = 1.34×10⁻³)
Mejia-Benitez et al. BMC Medical Genetics, 2013. A Chinese study found the G allele associated with increased BMI, fat mass percentage, and waist-to-height ratio in children, with effects varying by sex and pubertal stage. A Chinese Han adult study found the G allele more prevalent in healthy controls than in diabetic groups, suggesting the obesity risk mechanism is distinct from type 2 diabetes susceptibility at this locus.

The G allele frequency is approximately 0.43 in Europeans (risk allele frequency 41% in the Danish cohort) — making this a very common variant. The GG genotype, carrying the highest risk, occurs in ~18% of Europeans.

Practical Implications

Because GNPDA2's CNS role is glucose homeostasis rather than appetite, the primary intervention target for G allele carriers is glucose and insulin metabolism, not eating behavior. G allele carriers should prioritize dietary patterns that reduce glucose spikes and support insulin sensitivity, and monitor fasting glucose and insulin markers periodically to detect early insulin resistance.

In adipose tissue, the pro-adipogenic effect of GNPDA2 suggests that G allele carriers may have a modestly increased tendency to convert energy surplus into fat. Minimizing repeated glycemic surges — which drive hexosamine pathway flux upward — is a specific, mechanism-targeted strategy for this genotype.

Interactions

rs10938397 contributes to a polygenic obesity risk profile alongside FTO (rs9939609), MC4R (rs17782313), TMEM18 (rs6548238), and NEGR1 (rs2815752). Each operates through a distinct mechanism — FTO via thermogenesis, MC4R and TMEM18 via appetite suppression, NEGR1 via hypothalamic circuit development, and GNPDA2 via hexosamine-mediated glucose homeostasis and adipogenesis. GWAS evidence indicates these effects are additive: carrying risk alleles at multiple loci compounds the BMI increase, and a person with risk alleles at GNPDA2 plus FTO or MC4R faces a higher cumulative genetic burden than at either locus alone. No synergistic (multiplicative) interaction has been documented among these loci — their combined effect is the sum of their individual contributions.